LAUSR

The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), which has caused the COVID‐19 pandemic, is proved to involve multiple organs and systems, primarily targeting the cardiac and respiratory system. Cardiac arrhythmia, which induces by myocardial damage and subsequent cardiac dysfunction, is a major clinical manifestation in cardiac injury. Previous data revealed that 9%–16.7% of hospitalized patients with COVID‐19 suffering an unspecified arrhythmic event and contributed to 44% of those transferred to the ICU. The 17.6% of primary QTc prolongation and 0.38% of secondary torsade de pointes in COVID‐19 patients were disclosed by a detailed investigation. In addition, other drug interventions that appear to be independent of anti‐SARS‐CoV‐2 treatment, such as terlipressin, oxaliplatin, and so forth, are increasingly at risk of arrhythmias in the COVID‐19 patients with gastrointestinal (GI) bleeding.